中山恒赛生物科技有限公司申请II类会议

Group 1 - The core point of the article is that Zhongshan Hengsai Biotechnology Co., Ltd. has applied for a Type II meeting with the CDE, which is currently in processing status [1] - Type II meetings are held during critical stages of drug development, including pre-clinical trial meetings and meetings before new drug marketing authorization applications [1] - Zhongshan Hengsai Biotechnology was established in 2022, located in Zhongshan, with a registered and paid-in capital of 7.851022 million RMB [1] Group 2 - The company has made one external investment, participated in five bidding projects, and holds one patent [1] - The company possesses six administrative licenses [1] - Major shareholders include Liu Huining with 26.7145%, Cheng Xiangguo with 17.0164%, and Shanghai Xinke Investment Consulting Center (Limited Partnership) with 10.4716% [2]